Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Open Access
- 20 September 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (1), 36-52
- https://doi.org/10.1002/jbmr.3877
Abstract
Osteoporosis‐related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fracture among people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, and subcutaneous pharmacotherapies are efficacious and can reduce risk of future fracture. Patients need education, however, about the benefits and risks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first‐line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive but may be beneficial for selected patients at high risk. Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the early post‐fracture period, prompt treatment is recommended. Adequate dietary or supplemental vitamin D and calcium intake should be assured. Individuals being treated for osteoporosis should be re‐evaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects. Patients should be strongly encouraged to avoid tobacco, consume alcohol in moderation at most, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (e.g., hyperparathyroidism, chronic kidney disease).Keywords
This publication has 127 references indexed in Scilit:
- Characteristics of outdoor falls among older people: a qualitative studyBMC Geriatrics, 2013
- Exercise for improving outcomes after osteoporotic vertebral fractureEmergencias, 2013
- Epidemiology of falls and osteoporotic fractures: a systematic reviewClinicoEconomics and Outcomes Research, 2012
- Denosumab: mechanism of action and clinical outcomesInternational Journal Of Clinical Practice, 2012
- Interventions for preventing falls in older people living in the communityCochrane Database of Systematic Reviews, 2012
- Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older PersonsJournal of the American Geriatrics Society, 2011
- Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massDrug Design, Development and Therapy, 2010
- Incidental vertebral compression fractures in imaging studies: Lessons not learned by radiologistsWorld Journal of Radiology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Incidental Vertebral Fractures Discovered With Chest Radiography in the Emergency DepartmentArchives of Internal Medicine, 2005